Hoffmann-La Roche Inc.

Warren William McComas

Kyungjin Kim

Qingjie Ding

Paul Gillespie

Allen John Lovey

Agostino Perrotta

Jefferson Wright Tilley

Nan Jiang

Li Chen

Shawn David Erickson

Xin-Jie Chu

Sherrie Lynn Pietranico-Cole

Kevin Richard Guertin

Lida Qi

Qiang Zhang

Prabha Saba Karnachi

Chun Ma

John Guilfoyle Mullin, Jr

John Guifoyle Mullin, Jr

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

GPR119 receptor agonists

Novel diaminothiazoles of formula (I): are discussed. These compounds selectively inhibit the activity of Cdk4 and are thus useful in the treatment or control of cancer, in particular, the treatment or control of solid tumors. This invention also provides pharmaceutical compositions containing such compounds and methods of treating or controlling cancer, most particularly, the treatment or control of breast, lung, colon, and prostate tumors.

Diaminothiazoles

Disclosed are novel diaminothiazoles that are selective inhibitors of Cdk4. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds as well as intermediates useful in the preparation of the compounds.

Intermediates useful in the preparation of diaminothiazoles

Diaminothiazoles having antiproliferative activity

Growing community of inventors

Denville, NJ, United States of America

Warren William McComas